Von Willebrand Diseases
Conditions
Brief summary
The objective of this observational study HOPSCOTcH-WILL II is to provide an accurate and detailed account of current Von Willebrand Disease (VWD) therapeutic management by collecting real-life data on hemorrhagic treated events in the 5 Western French Hemophilia Treatment Center. The HOPSCOTCH-WILL II study aims to describe therapeutic management of patients with VWD, following the provision of a recombinant drug in France; It will also permit to carry out a budget impact analysis to quantify the economic significance of this new era.
Interventions
OTHERno intervention
no intervention
Sponsors
Nantes University Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Constitutional Von Willebrand Disease patient, of any severity, with or without Von Willebrand Factors inhibitors * Patient included in the research database BERHLINGO * Patient treated or not by desmopressin or Von Willebrand Factor/FVIII/by-passing agents available on the French market (at baseline) * Patient who agrees to participate in the HOPSCOTcH-Will II and followed in one of the 5 investigator centers
Exclusion criteria
\- Patients under guardianship
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Observational study, description of the global therapeutic modalities required for severe treated hemorrhagic events in constitutional Von Willebrand Disease patients of any severity | 4 years | Data collection for evaluation of Clotting factors quantities used by collection of treatments for severe hemorrhagic events |
Countries
France
Outcome results
None listed